loader
Please Wait
Applying Filters...

Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Technical details about Fondaparinux, learn more about the structure, uses, toxicity, action, side effects and more

    Client Email Product
    Menu

    Fondaparinux

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Forms

    DRUG PRODUCT COMPOSITION

    RELATED EXCIPIENT COMPANIES

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    REF. STANDARDS & IMPURITIES

    DIGITAL CONTENT

    PharmaCompass

    Inke S.A: APIs manufacturing plant.

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    2D Structure
    1. Also known as: 114870-03-0, Arixtra, Quixidar, Fondaparin sodium, Sr-90107a, Org 31540
    Molecular Formula
    C31H43N3Na10O49S8
    Molecular Weight
    1728.1  g/mol
    InChI Key
    XEKSTYNIJLDDAZ-JASSWCPGSA-D
    FDA UNII
    X0Q6N9USOZ
    Synthetic pentasaccharide that mediates the interaction of HEPARIN with ANTITHROMBINS and inhibits FACTOR Xa; it is used for prevention of VENOUS THROMBOEMBOLISM after surgery.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    decasodium;(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5R,6R)-6-[(2R,3S,4S,5R,6R)-2-carboxylato-4-hydroxy-6-[(2R,3S,4R,5R,6S)-4-hydroxy-6-methoxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)oxan-3-yl]oxy-5-sulfonatooxyoxan-3-yl]oxy-5-(sulfonatoamino)-4-sulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxy-3-[(2R,3R,4R,5S,6R)-4,5-dihydroxy-3-(sulfonatoamino)-6-(sulfonatooxymethyl)oxan-2-yl]oxy-4,5-dihydroxyoxane-2-carboxylate
    2.1.2 InChI
    InChI=1S/C31H53N3O49S8.10Na/c1-69-27-9(33-85(48,49)50)13(37)17(6(74-27)3-71-88(57,58)59)76-31-22(83-91(66,67)68)16(40)21(24(81-31)26(43)44)79-29-10(34-86(51,52)53)19(82-90(63,64)65)18(7(75-29)4-72-89(60,61)62)77-30-15(39)14(38)20(23(80-30)25(41)42)78-28-8(32-84(45,46)47)12(36)11(35)5(73-28)2-70-87(54,55)56;;;;;;;;;;/h5-24,27-40H,2-4H2,1H3,(H,41,42)(H,43,44)(H,45,46,47)(H,48,49,50)(H,51,52,53)(H,54,55,56)(H,57,58,59)(H,60,61,62)(H,63,64,65)(H,66,67,68);;;;;;;;;;/q;10*+1/p-10/t5-,6-,7-,8-,9-,10-,11-,12-,13-,14-,15-,16+,17-,18-,19-,20+,21+,22-,23+,24-,27+,28-,29-,30-,31-;;;;;;;;;;/m1........../s1
    2.1.3 InChI Key
    XEKSTYNIJLDDAZ-JASSWCPGSA-D
    2.1.4 Canonical SMILES
    COC1C(C(C(C(O1)COS(=O)(=O)[O-])OC2C(C(C(C(O2)C(=O)[O-])OC3C(C(C(C(O3)COS(=O)(=O)[O-])OC4C(C(C(C(O4)C(=O)[O-])OC5C(C(C(C(O5)COS(=O)(=O)[O-])O)O)NS(=O)(=O)[O-])O)O)OS(=O)(=O)[O-])NS(=O)(=O)[O-])O)OS(=O)(=O)[O-])O)NS(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
    2.1.5 Isomeric SMILES
    CO[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)COS(=O)(=O)[O-])O[C@H]2[C@@H]([C@H]([C@@H]([C@@H](O2)C(=O)[O-])O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)COS(=O)(=O)[O-])O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)[O-])O[C@@H]5[C@@H]([C@H]([C@@H]([C@H](O5)COS(=O)(=O)[O-])O)O)NS(=O)(=O)[O-])O)O)OS(=O)(=O)[O-])NS(=O)(=O)[O-])O)OS(=O)(=O)[O-])O)NS(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
    2.2 Other Identifiers
    2.2.1 UNII
    X0Q6N9USOZ
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Arixtra

    2. Fondaparinux

    3. Quixidar

    2.3.2 Depositor-Supplied Synonyms

    1. 114870-03-0

    2. Arixtra

    3. Quixidar

    4. Fondaparin Sodium

    5. Sr-90107a

    6. Org 31540

    7. Sr 90107a

    8. Fondaparinux Sodium For Assay

    9. Org-31540

    10. Fondaparinux Sodium Identification

    11. X0q6n9usoz

    12. Ic-851589

    13. Xantidar

    14. Arixtra (tn)

    15. Unii-x0q6n9usoz

    16. Fondaparinux Sodium [usan]

    17. Fondaparinux Sodium [usan:inn:ban]

    18. Gsk-576428

    19. Ic 85158

    20. Sr-90107

    21. Chembl1200644

    22. Fondaparinux Sodium [mi]

    23. Fondaparinux Sodium [inn]

    24. Fondaparinux Sodium [jan]

    25. Dtxsid501027612

    26. Fondaparinux Sodium [mart.]

    27. Fondaparinux Sodium (jan/usp/inn)

    28. Fondaparinux Sodium [usp-rs]

    29. Fondaparinux Sodium [who-dd]

    30. Natural Heparin Pentasaccharide Sodium

    31. Akos005146286

    32. Fondaparinux Sodium [ema Epar]

    33. Ccg-270693

    34. Fondaparinux Sodium [orange Book]

    35. As-80003

    36. Fondaparinux Sodium [usp Monograph]

    37. C71476

    38. D01844

    39. A803253

    40. Q421218

    41. Alpha-d-glucopyranoside, Methyl O-2-deoxy-6-o-sulfo-2-(sulfoamino)-alpha-d-glucopyranosyl-(1-4)-o-beta-d-glucopyranuronosyl(1-4)-o-2-deoxy-3,6-di-o-sulfo-2-(sulfoamino)-alpha-d-glucopyranosyl-(1-4)-o-2-o-sulfo-alpha-l-idopyranuronosyl-(1-4)-2-deoxy-2-(sulfoamino)-, 6-(hydrogen Sulfate), Decasodium Salt

    42. Decasodium 6-[6-[2-carboxylato-4-hydroxy-6-[4-hydroxy-6-methoxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)tetrahydropyran-3-yl]oxy-5-sulfonatooxy-tetrahydropyran-3-yl]oxy-5-(sulfonatoamino)-4-sulfonatooxy-2-(sulfonatooxymethyl)tetrahydropyran-3-yl]oxy-3-[4;fondaparinux Sodium

    43. Methly O-2-deoxy-6-o-sulfo-2-(sulfoamino)-alpha-d-glucopyranosyl-(1-4)-o-beta-d-glucopyranuronosyl-(1-4)-o-2-deoxy-3,6-di-o-sulfo-2-(sulfoamino)-alpha-d-glucopyranosyl-(1-4)-o-2-o-sulfo-alpha-l-idopyranuronosyl-(1-4)-2-deoxy-6-o-sulfo-2-(sulfoamino)-alpha-d-glucopyranoside, Decasodium Salt

    2.4 Create Date
    2005-06-24
    3 Chemical and Physical Properties
    Molecular Weight 1728.1 g/mol
    Molecular Formula C31H43N3Na10O49S8
    Hydrogen Bond Donor Count9
    Hydrogen Bond Acceptor Count52
    Rotatable Bond Count20
    Exact Mass1726.7707769 g/mol
    Monoisotopic Mass1726.7707769 g/mol
    Topological Polar Surface Area901 Ų
    Heavy Atom Count101
    Formal Charge0
    Complexity3330
    Isotope Atom Count0
    Defined Atom Stereocenter Count25
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count11
    4 Drug and Medication Information
    4.1 Drug Information
    1 of 4  
    Drug NameArixtra
    Drug LabelARIXTRA (fondaparinux sodium) Injection is a sterile solution containing fondaparinux sodium. It is a synthetic and specific inhibitor of activated Factor X (Xa). Fondaparinux sodium is methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)--D-glucopyranosyl-(1...
    Active IngredientFondaparinux sodium
    Dosage FormInjectable
    RouteSubcutaneous
    Strength5mg/0.4ml; 2.5mg/0.5ml; 7.5mg/0.6ml; 10mg/0.8ml
    Market StatusPrescription
    CompanyAgi

    2 of 4  
    Drug NameFondaparinux sodium
    PubMed HealthFondaparinux (Injection)
    Drug ClassesAnticoagulant
    Drug LabelARIXTRA (fondaparinux sodium) Injection is a sterile solution containing fondaparinux sodium. It is a synthetic and specific inhibitor of activated Factor X (Xa). Fondaparinux sodium is methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)--D-glucopyranosyl-(1...
    Active IngredientFondaparinux sodium
    Dosage FormInjectable
    RouteSubcutaneous
    Strength2.5mg/0.5ml; 7.5mg/0.6ml; 5mg/0.4ml; 10mg/0.8ml
    Market StatusPrescription
    CompanyDr Reddys Labs

    3 of 4  
    Drug NameArixtra
    Drug LabelARIXTRA (fondaparinux sodium) Injection is a sterile solution containing fondaparinux sodium. It is a synthetic and specific inhibitor of activated Factor X (Xa). Fondaparinux sodium is methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)--D-glucopyranosyl-(1...
    Active IngredientFondaparinux sodium
    Dosage FormInjectable
    RouteSubcutaneous
    Strength5mg/0.4ml; 2.5mg/0.5ml; 7.5mg/0.6ml; 10mg/0.8ml
    Market StatusPrescription
    CompanyAgi

    4 of 4  
    Drug NameFondaparinux sodium
    PubMed HealthFondaparinux (Injection)
    Drug ClassesAnticoagulant
    Drug LabelARIXTRA (fondaparinux sodium) Injection is a sterile solution containing fondaparinux sodium. It is a synthetic and specific inhibitor of activated Factor X (Xa). Fondaparinux sodium is methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)--D-glucopyranosyl-(1...
    Active IngredientFondaparinux sodium
    Dosage FormInjectable
    RouteSubcutaneous
    Strength2.5mg/0.5ml; 7.5mg/0.6ml; 5mg/0.4ml; 10mg/0.8ml
    Market StatusPrescription
    CompanyDr Reddys Labs

    4.2 Drug Indication

    * 1. 5-mg/0. 3-ml and 2. 5-mg/0. 5-ml solution for injection:

    Prevention of venous thromboembolic events (VTE) in adults undergoing major orthopaedic surgery of the lower limbs such as hip fracture, major knee surgery or hip-replacement surgery.

    Prevention of VTE in adults undergoing abdominal surgery who are judged to be at high risk of thromboembolic complications, such as patients undergoing abdominal cancer surgery.

    Prevention of VTE in adult medical patients who are judged to be at high risk for VTE and who are immobilised due to acute illness such as cardiac insufficiency and / or acute respiratory disorders, and / or acute infectious or inflammatory disease.

    Treatment of adults with acute symptomatic spontaneous superficial-vein thrombosis of the lower limbs without concomitant deep-vein thrombosis.

    * 2. 5-mg/0. 5-ml solution for injection:

    Treatment of unstable angina or non-ST-segment-elevation myocardial infarction (UA/NSTEMI) in adult patients for whom urgent (< 120 mins) invasive management (PCI) is not indicated.

    infarction (STEMI) in adult patients who are managed with thrombolytics or who initially are to receive no other form of reperfusion therapy.

    * 5-mg/0. 4-ml, 7. 5-mg/0. 6-ml and 10-mg/0. 8-ml solution for injection:

    Treatment of adults with acute deep-vein thrombosis (DVT) and treatment of acute pulmonary embolism (PE), except in haemodynamically unstable patients or patients who require thrombolysis or pulmonary embolectomy.

    1. 5 mg/0. 3 ml and 2. 5 mg/0. 5 ml, solution for injection:

    Prevention of Venous Thromboembolic Events (VTE) in patients undergoing major orthopaedic surgery of the lower limbs such as hip fracture, major knee surgery or hip replacement surgery.

    Prevention of Venous Thromboembolic Events (VTE) in patients undergoing abdominal surgery who are judged to be at high risk of thromboembolic complications, such as patients undergoing abdominal cancer surgery (see section 5. 1).

    Prevention of Venous Thromboembolic Events (VTE) in medical patients who are judged to be at high risk for VTE and who are immobilised due to acute illness such as cardiac insufficiency and/or acute respiratory disorders, and/or acute infectious or inflammatory disease.

    2. 5 mg/0. 5 ml, solution for injection:

    Treatment of unstable angina or non-ST segment elevation myocardial infarction (UA/NSTEMI) in patients for whom urgent (< 120 mins) invasive management (PCI) is not indicated (see sections 4. 4 and 5. 1).

    Treatment of ST segment elevation myocardial infarction (STEMI) in patients who are managed with thrombolytics or who initially are to receive no other form of reperfusion therapy.

    5 mg/0. 4 ml, 7. 5 mg/0. 6 ml and 10 mg/0. 8 ml solution for injection:

    Treatment of acute Deep Vein Thrombosis (DVT) and treatment of acute Pulmonary Embolism (PE), except in haemodynamically unstable patients or patients who require thrombolysis or pulmonary embolectomy.

    5 Pharmacology and Biochemistry
    5.1 MeSH Pharmacological Classification

    Factor Xa Inhibitors

    Endogenous factors and drugs that inhibit or block the activity of FACTOR XA. (See all compounds classified as Factor Xa Inhibitors.)

    5.2 FDA Pharmacological Classification
    5.2.1 Pharmacological Classes
    Factor Xa Inhibitors [MoA]; Factor Xa Inhibitor [EPC]
    5.3 ATC Code

    B01AX05

    B01AX05

    Post Enquiry
    POST ENQUIRY